Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
54
CLMT Quote, Financials, Valuation and Earnings
Last price:
$16.03
Seasonality move
:
10.37%
Day range:
$15.40 - $16.50
52-week range:
$7.68 - $25.29
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.33x
P/B ratio:
--
Volume:
706.2K
Avg. volume:
1.2M
1-year change:
1.19%
Market cap:
$1.4B
Revenue:
$4.2B
EPS (TTM):
-$4.00
Analysts' Opinion
-
Consensus RatingCalumet has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 3 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.00, Calumet has an estimated upside of 17.21% from its current price of $16.21.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 25.97% downside risk from its current price of $16.21.
Fair Value
-
According to the consensus of 5 analysts, Calumet has 17.21% upside to fair value with a price target of $19.00 per share.
CLMT vs. S&P 500
-
Over the past 5 trading days, Calumet has overperformed the S&P 500 by 1.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Calumet does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Calumet revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Calumet reported revenues of $993.9M.
Earnings Growth
-
Calumet has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Calumet reported earnings per share of -$1.87.
Enterprise value:
3.9B
EV / Invested capital:
--
Price / LTM sales:
0.33x
EV / EBIT:
217.40x
EV / Revenue:
0.92x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-28.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
217.40x
Gross Profit (TTM):
$70.9M
Return On Assets:
-12.57%
Net Income Margin (TTM):
-8.2%
Return On Equity:
--
Return On Invested Capital:
-17.89%
Operating Margin:
-11.16%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $4.6B | $4.1B | $4.2B | $1B | $993.9M | |
| Gross Profit | $415.6M | $433.6M | $70.9M | $78.5M | -$81.4M | |
| Operating Income | $192.9M | $264M | -$137.1M | $36.3M | -$110.9M | |
| EBITDA | $117.5M | $222.5M | -$107M | $19.4M | -$103.1M | |
| Diluted EPS | -$0.63 | -$0.13 | -$4.00 | -$0.51 | -$1.87 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $602.6M | $691.8M | $799.9M | $811.7M | $917.9M | |
| Total Assets | $1.9B | $2.2B | $2.8B | $2.7B | $2.8B | |
| Current Liabilities | $831.7M | $1.1B | $1.3B | $824.4M | $869.1M | |
| Total Liabilities | $2.1B | $2.7B | $3B | $3B | $3.4B | |
| Total Equity | -$273.5M | -$463.8M | -$276.1M | -$284.1M | -$616.7M | |
| Total Debt | $1.4B | $1.4B | $1.7B | $2.1B | $2.3B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $76.8M | -$82.2M | -$63M | -$94M | -$110.6M | |
| Cash From Investing | -$599.4M | -$161.4M | $21.1M | -$20M | $77.8M | |
| Cash From Financing | $479.2M | $263.8M | $213.9M | $130.7M | $190.3M | |
| Free Cash Flow | -$522.6M | -$243.6M | -$137.3M | -$114M | -$128.2M | |
CLMT
Sector
Market Cap
$1.4B
$57.4M
Price % of 52-Week High
64.1%
65.99%
Dividend Yield
0%
0%
Shareholder Yield
--
4.75%
1-Year Price Total Return
1.19%
-23.9%
Beta (5-Year)
0.932
0.655
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$16.39
200-day SMA
Sell
Level
$16.57
Bollinger Bands (100)
Buy
Level
11.04 - 15.48
Chaikin Money Flow
Sell
Level
-401.9K
20-day SMA
Buy
Level
$16.19
Relative Strength Index (RSI14)
Buy
Level
56.25
ADX Line
Sell
Level
17.53
Williams %R
Neutral
Level
-42.2633
50-day SMA
Buy
Level
$14.62
MACD (12, 26)
Buy
Level
4.46
25-day Aroon Oscillator
Buy
Level
20
On Balance Volume
Sell
Level
-1.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.066)
Sell
CA Score
(Annual)
Level (-2.7251)
Buy
Beneish M-Score
(Annual)
Level (-2.3449)
Buy
Momentum Score
Level (4)
Sell
Ohlson Score
Level (4.0188)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
Stock Forecast FAQ
In the current month, CLMT has received 2 Buy ratings 3 Hold ratings, and 0 Sell ratings. The CLMT average analyst price target in the past 3 months is $19.00.
-
Where Will Calumet Stock Be In 1 Year?
According to analysts, the consensus estimate is that Calumet share price will rise to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Calumet?
Analysts are divided on their view about Calumet share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Calumet is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Calumet's Price Target?
The price target for Calumet over the next 1-year time period is forecast to be $19.00 according to 5 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is CLMT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Calumet is a Hold. 3 of 5 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CLMT?
You can purchase shares of Calumet via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Calumet shares.
-
What Is The Calumet Share Price Today?
Calumet was last trading at $16.03 per share. This represents the most recent stock quote for Calumet. Yesterday, Calumet closed at $16.21 per share.
-
How To Buy Calumet Stock Online?
In order to purchase Calumet stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
